This article is more than 5 years old. Information may no longer be current.

FDA grants orphan drug status to eye drop treatment for keratoconus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA granted orphan drug designation to IVMED-80, an eye drop used for cross-linking the cornea to treat keratoconus.

“Receiving orphan drug designation is an important regulatory milestone, and we are pleased that IVMED-80 for keratoconus has been granted this status,” Gerald Simmons, CEO of iVeena Delivery Systems, said in a press release from the company. “We are developing IVMED-80 to offer another option in the treatment of keratoconus. The prospect of treating keratoconus with only a daily eye drop is very attractive, and our team is committed to advancing the clinical development.”

IVMED-80 biomechanically strengthens the cornea through daily administration of an eye drop.

IVeena Delivery System said it will begin clinical development in 2018.